Assessing efficacy and safety of genome EDITing approaches for Sickle Cell Disease

Informazioni relative al progetto

EDITSCD

ID dell’accordo di sovvenzione: 101057659

DOI 10.3030/101057659

Data della firma CE 24 Maggio 2022

Data di avvio 1 Settembre 2022

Data di completamento 31 Agosto 2027

Finanziato da

• Health

Costo totale € 6 532 000,00

Contributo UE € 6 532 000,00

Coordinato da

IMAGINE INSTITUT DES MALADIES GENETIQUES NECKER ENFANTS MALADES FONDATION
France

Risultati finali

Documents, reports (2)

Data Management Plan 2

We will revise the data management plan (see paragraph 1.2.6) at month 18

Data Management Plan 1

A document describing the data management plan (see paragraph 1.2.6) will be produced and provided at month 6

Websites, patent fillings, videos etc. (1)

Project website and logo

A web page will be created in English for information of patients, families, patient organizations, the general public, health care providers, financial actors on the aims and progress of the project.

Pubblicazioni

Peer reviewed articles (1)

Clinical genome editing to treat sickle cell disease—A brief update

Autori: Parinaz Zarghamian; Julia Klermund; Toni Cathomen
Pubblicato in: Crossref, 2023, ISSN 2296-858X
Editore: Frontiers in Medecine
DOI: 10.3389/fmed.2022.1065377